Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 4/20 | 0.57 |
| ▸ | HTR1B | P28222 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14555321 | 0.87 | ATM (0.47) | HTR1DHTR1BHTR2AATMKIF11 | |
| SCHEMBL10147746 | 0.85 | KIF11 (0.49) | HTR1DHTR1BHTR2AATMLMNA | |
| Ethoxycarbonyl Group SCHEMBL27719083 | 0.83 | HTR1D (0.46) | HTR1DHTR1BHTR2AATMTRPA1 | |
| SCHEMBL20077509 | 0.82 | HTR1D (0.44) | HTR1DHTR1BHTR2AATMGAA | |
| SCHEMBL15912345 | 0.81 | HTR1D (0.57) | HTR1DHTR1BHTR2AKDM4EGAA | |
| SCHEMBL18713928 | 0.80 | ATM (0.44) | HTR1DHTR1BHTR2AATMLMNA | |
| SCHEMBL12376509 | 0.79 | HTR1D (0.55) | HTR1DHTR1BHTR2AKDM4EGAA | |
| SCHEMBL15701663 | 0.79 | HTR1D (0.55) | HTR1DHTR1BHTR2AKDM4EGAA | |
| SCHEMBL22479037 | 0.79 | HTR1D (0.55) | HTR1DHTR1BHTR2ALMNAKDM4E | |
| SCHEMBL21127664 | 0.77 | HTR1D (0.53) | HTR1DHTR1BHTR2AKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2023-05-04 | — | — | US | disclosed |
| US-11369611-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-06-16 | — | — | US | disclosed |
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | GENFIT (FR) | 2021-07-06 | — | — | US | disclosed |
| US-20200323854-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2020-10-15 | — | — | US | disclosed |
| US-10758539-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190216812-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2019-07-18 | — | — | US | disclosed |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-9833453-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20130085238-A1 | BIOCOMPATIBLE POLYMERS FOR MEDICAL DEVICES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11052092-B2 | N-{[2-(piperidin-1-yl)phenyl](phenyl)methyl}-2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-7-yl)acetamide derivatives and related compounds as ROR-gamma modulators for treating autoimmune diseases | RORA, RORC, RORB | HTR1D 2935/4885HTR1B 3821/4885HTR2A 2851/4885 |
| US-20180118751-A1 | IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIK5, GRIN1, GRIN3A | HTR1D 442/4885HTR1B 490/4885HTR2A 332/4885 |
| US-10758539-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | HTR1D 4050/4885HTR1B 2534/4885HTR2A 3366/4885 |
| US-11369611-B2 | Therapeutic compounds and uses thereof | MUC1, CFTR, SLC26A4 | HTR1D 4050/4885HTR1B 2534/4885HTR2A 3366/4885 |
| US-20220185831-A1 | STAT3 PROTEIN DEGRADERS | STAT3, JAK2, STAT5A | HTR1D 3677/4885HTR1B 2325/4885HTR2A 1998/4885 |
| US-20190216812-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | HTR1D 4050/4885HTR1B 2534/4885HTR2A 3366/4885 |
| US-20230133504-A1 | METHOD OF TREATING GRAFT-VERSUS-HOST DISEASE | HLA-DRB1, CD74, HLA-C | HTR1D 4169/4885HTR1B 3381/4885HTR2A 2959/4885 |
| US-20200323854-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | HTR1D 4050/4885HTR1B 2534/4885HTR2A 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.